Shamburg News · 8-K filed Oct 8, 2026, 4:14 PM EDT
Aardvark Therapeutics Appoints David Zhang, Ph.D., MBA, as Class II Director
AARD · Aardvark Therapeutics, Inc.
- Leadership change
- Other event
- Materiality: medium
On October 6, 2026, Aardvark Therapeutics' board appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II director effective October 7, 2026. Dr. Zhang is Chief Strategy Officer of Abivax S.A. and previously served at Alumis Inc. and MyoKardia, Inc. He receives $40,000 per year in prorated cash compensation and an option granted October 7, 2026 equal to $500,000 divided by the per-share grant date fair value, vesting monthly over 36 months. The company also issued a press release on October 8, 2026 announcing the appointment.
Source: SEC EDGAR, Form 8-K, Items 5.02, 8.01, 9.01, accession 0001193125-26-417935.
Written from the filing by Shamburg Markets. Figures are as reported by the company.